Determination of the Clonality Profile in Myeloproliferative Neoplasms and Association With the Thrombotic Complications (CLOJAK)
Ориентир для пациента и семьи
Простыми словами
Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.
- Что изучают
- В протоколе указаны: Blood sampling.
- Кому может быть актуально
- Состояния в реестре: Myeloproliferative Neoplasm. Базовые параметры: от 18 лет · Все.
- Что важно проверить
- Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
- Где проводится
- Франция
- Следующий шаг
- Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Не всё понятно в терминах? Прочитайте наш гид для пациентов →
Обзор
Myeloproliferative Neoplasms (MPN) are associated with an increased risk of thrombosis. Platelets, red blood cells (RBC), leukocytes and endothelial cells are involved in these complications. An association with the JAK2V617F allele burden assessed in leukocytes has also been suggested. In some patients the allele burden measured in platelets and red blood cells is higher than the one determined in leukocytes. Our project aims at associating the risk of thrombosis with the allele burden determined in the cell populations (platelets, red blood cells, granulocytes and endothelial cells) and identifying high-risk clonality profiles.
Подробное описание
Myeloproliferative Neoplasms (MPN) are hematological malignancies associated with an increased risk of thrombosis. Although different cell types have been involved in these complications (platelets, red blood cells, leucocytes and endothelial cells), there do not exist any reliable biomarker to predict the thrombotic risk in MPN patients. While some studies suggested that the JAK2V617F allele burden measured in leukocytes was associated with the risk of thrombosis, other studies did not confirm these results. Besides, a recent work demonstrated that in some patients, the JAK2V617F allele burden measured in platelets and red blood cells was higher than the one determined in leukocytes. Moreover, some patients present JAK2V617F mutated endothelial cells, known as pro-thrombotic in in vitro and animal models. The CLOJAK project will search for an association between the thrombotic risk in MPN and the proportion of cells carrying the JAK2V617F mutation in erythroid cells and platelets or its presence in endothelial cells. The objective is to determine a clonality profile (i.e. the profile of repartition of the JAK2V617F allele burden in the different hematopoietic and endothelial lineages) associated with the occurrence of thrombosis in MPN patients.
One hundred and twenty PV and ET patients will be studied at diagnosis. Their platelets, red blood cells, granulocytes and endothelial cells will be isolated. The JAK2V617F allele burden will be measured in these cells thanks to a digital PCR technic. An association between the clonality profile and the existence of a thrombosis at diagnosis, the MPN phenotype (PV or ET), the IPSET-thrombosis score and the type of thrombosis (venous, arterial, splanchnic) will be searched.
Вмешательства
- Процедура Blood sampling
A specific blood sampling will be performed in addition to the classical evaluations that are performed in routine practice
Первичные конечные точки
- History of thrombosis at MPN diagnosis [Срок оценки: At inclusion]
Вторичные конечные точки (8)
- The JAK2V617F allele burden measured in red blood cells [Срок оценки: At inclusion]
- The JAK2V617F allele burden measured in platelets [Срок оценки: At inclusion]
- The JAK2V617F allele burden measured in granulocytes [Срок оценки: At inclusion]
- The presence of the JAK2V617F mutation in endothelial cells [Срок оценки: At inclusion]
- The clonality profile [Срок оценки: At inclusion]
- The type of MPN according to the 2016 WHO classification of hematological malignancies [Срок оценки: At inclusion]
- The IPSET-Thrombosis score [Срок оценки: At inclusion]
- The type of thrombosis [Срок оценки: At inclusion]
Критерии участия
Критерии включения
- Adult patient (age ≥ 18 years)
- Inclusion at diagnosis or during the year following the diagnosis of PV or ET (2016 WHO criteria except bone marrow biopsy that is optional), before introduction of a cytoreductive treatment
- Patient carrying a JAK2V617F mutation
- Subject registered with a social security scheme
- Written informed consent obtained
- Acceptance of inclusion in the FIMBANK registry (specific consent form needed)
Критерии исключения
- ET or PV Patient not carrying a JAK2V617F mutation
- Patient with cytoreductive treatment (hydroxyurea, anagrelide, interferon, ruxolitinib or other chemotherapy) at the time of blood sampling
- Person under judicial safeguards, trustee or curatorship
- Person unable to give her consent
- Non-cooperative person
- Exclusion period after another clinical study or participation to another clinical study in the 30 days before inclusion
Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.
Здоровые добровольцы: Нет
Дизайн исследования
- Модель наблюдения
- Когортное
Центры проведения
Франция · 11 центров
- CHU d'Angers, Service Maladies du Sang — Angers
- CH de Bayonne, Service Hématologie Clinique — Bayonne
- CHU de Bordeaux, Service Médecine Interne et Maladies Infectieuses — Bordeaux
- Institut Bergonié, Service Hématologie Clinique — Bordeaux
- CHU de Brest, Service Hématologie Clinique — Brest
- CH de Dax, Service Hématologie Clinique — Dax
- CH de Libourne, Service Hématologie Clinique — Libourne
- CH de Mont de Marsan, Service Oncologie — Mont-de-Marsan
- … и ещё 3 центра
Идентификаторы
NCT: NCT05839717 · CHUBX 2022/16